CYTOVATION
Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
CYTOVATION
Industry:
Biotechnology Life Science Medical
Founded:
2001-01-01
Address:
Bergen, Hordaland, Norway
Country:
Norway
Website Url:
http://www.cytovation.com
Total Employee:
1+
Status:
Active
Contact:
+47 55 97 09 60
Total Funding:
200 M NOK
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Current Advisors List
Board_member
Advisor
Board_member
Current Employees Featured
Kjell-Inge Arnevig CEO @ Cytovation
CEO
2014-09-01
Lars Prestegarden Chief scientific officer @ Cytovation
Chief scientific officer
Founder
Investors List
Canica
Canica investment in Series A - Cytovation
Project Sandwater
Project Sandwater investment in Series A - Cytovation
Official Site Inspections
http://www.cytovation.com Semrush global rank: 4.31 M Semrush visits lastest month: 2.66 K
- Host name: webcluster41.webpod11-cph3.one.com
- IP address: 77.111.240.168
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Cytovation"
Cytovation - Precision medicine for patients with β …
Cytovation’s technology is broadly applicable across solid tumor types, particularly those driven by the Wnt/β-catenin signaling pathway. Learn more about our Pipeline. News. Stay up to date on our latest news and …See details»
Cytovation ASA - Leading the way in immunotherapy
Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly …See details»
Cytovation - Crunchbase Company Profile & Funding
Cytovation AS is a privately-held biotech company, specialising . View contacts for Cytovation to access new leads and connect with decision-makers.See details»
Cytovation - LinkedIn
Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells.See details»
Cytovation ASA - Our Technology
Our approach eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment and …See details»
Cytovation 2025 Company Profile: Valuation, Funding …
Cytovation General Information Description. Developer of a synthetic peptide designed to provide treatment for benign skin tumors and various types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action …See details»
Cytovation - Funding, Financials, Valuation & Investors - Crunchbase
Cytovation AS is a privately-held biotech company, specialising . New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has this …See details»
Press Release Distribution and Management - GlobeNewswire
Feb 15, 2023 Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2, 2023 – Cytovation ASA, a clinical stage immune-oncology …See details»
Cytovation Company Profile - Craft
Cytovation is a clinical-stage immune-oncology company that provides engineering synthetic peptides. It develops CyPep-1, a tumor membrane-targeted immunotherapy for the treatment …See details»
Cytovation Company Information - Funding, Investors, and More
The company Cytovation has raised a total of $20.37m in funding over 1 rounds. Key Insights: Series A: $20.37m; 2022. Cytovation Series A (2022, $20M) $20.37m. Similar startup. Wattif …See details»
Cytovation Appoints Martin Dewhurst to its Board of Directors
Feb 13, 2025 Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 12, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its …See details»
Cytovation ASA - Our Pipeline
Cytovation develops treatments for solid tumors in oncology and rare diseases. Menu Menu; A new approach. CY-101 helps the immune system to fight cancer by exposing tumor …See details»
Cytovation Appoints Martin Dewhurst to its Board of
Feb 13, 2025 Cytovation ASA is a clinical stage immune-oncology company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual …See details»
Cytovation AS kicks-off with $20m Series A financing
Jan 25, 2022 Norway's immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater. ADVERTISEMENT. The Bergen University …See details»
Cytovation Appoints Martin Dewhurst to its Board of Directors
Feb 13, 2025 Brings over 30 years of life sciences industry experience; Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 13, 2025 – Cytovation ASA, a clinical …See details»
CY-101 by Cytovation for Triple-Negative Breast Cancer (TNBC ...
Dec 30, 2024 CytovationA (Cytovation) is a biotech company that develops novel therapeutic agents for skin diseases and infections. The company’s lead candidate includes CyPep-1 is a …See details»
Cytovation Announces Clinical Collaboration with MSD to Evaluate …
Jun 30, 2021 Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell …See details»
Cancer Research UK, Cytovation and the Norwegian Cancer …
Jan 23, 2025 Cytovation ASA is a clinical stage biotech company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual mechanism of …See details»
Cytovation Appoints Martin Dewhurst to its Board of Directors
Feb 13, 2025 Brings over 30 years of life sciences industry experience; Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 12, 2025 - Cytovation ASA, a clinical …See details»
Cytovation to present full safety and efficacy data from the CICILIA ...
Sep 16, 2024 CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the …See details»